Necessity of intracellular cyclic AMP in inducing gastric acid secretion via muscarinic M3 and cholecystokinin2 receptors on parietal cells in isolated mouse stomach.
The existence of a direct action of acetylcholine and gastrin on muscarinic M3 and cholecystokinin2 (CCK2) receptors on gastric parietal cells has not yet been convincingly established because these stimulated acid secretions are remarkably inhibited by histamine H2 receptor antagonists. In the present study, we investigated the necessity of intracellular cyclic AMP in inducing gastric acid secretion via muscarinic M3 and CCK2 receptors on parietal cells using an isolated mouse stomach preparation. Bethanechol (10-300 microM) produced a marked increase in acid output and this increase was completely blocked by famotidine (10 microM). In the presence of famotidine, bethanechol (1-30 microM) augmented the acid secretory response to dibutyryl AMP (200 microM) in a concentration-dependent manner. The augmentation was blocked by atropine (1 microM), 4-DAMP (0.1 microM), a muscarinic M3-selective antagonist, and by Ca2+ exclusion from the serosal nutrient solution. Pentagastrin (0.3-3 microM) also concentration-dependently stimulated gastric acid secretion, but the effect was completely inhibited by famotidine. In the presence of famotidine, pentagastrin (0.1-0.3 microM) elicited a definite potentiation of the acid secretory response to dibutyryl cyclic AMP (200 microM). This potentiation was inhibited by YM022 (1 microM), a CCK2 receptor antagonist, and by exclusion of Ca2+ from the serosal nutrient solution. The present results suggest that gastric acid secretion via the activation of muscarinic M3 and CCK2 receptors on the parietal cells is induced by activation of the cyclic AMP-dependent secretory pathway.
Ochi
Yasuo
Y
Laboratory of Molecular Pharmacology and Pharmacotherapeutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
Horie
Syunji
S
Maruyama
Takako
T
Watanabe
Kazuo
K
Yano
Shingo
S
D000704:Analysis of Variance; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D018723:Bethanechol / Q000037:antagonists & inhibitors / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D015738:Famotidine / Q000494:pharmacology; D005744:Gastric Acid / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D008297:Male; D051379:Mice; D010295:Parietal Cells, Gastric / Q000378:metabolism*; D010418:Pentagastrin / Q000037:antagonists & inhibitors / Q000378:metabolism; D043887:Receptor, Cholecystokinin B / Q000378:metabolism*; D043587:Receptor, Muscarinic M3 / Q000378:metabolism*
D006635:Histamine H2 Antagonists; D043887:Receptor, Cholecystokinin B; D043587:Receptor, Muscarinic M3; D018723:Bethanechol; D001569:Benzodiazepines; C087260:YM 022; D015738:Famotidine; D000242:Cyclic AMP; D010418:Pentagastrin; D002118:Calcium